Anxiety: Neurobiologic underpinnings

Psychiatric Annals

Volumn 28, Issue 3, 1998, Pages 130-138

  Longo, Lance P ^a,b,c  

^a AURORA SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032391308     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19980301-08     Document Type: Article

References (88)

1. Salzman C, Miyawaki E, Ie Bars P, Kerrihard T. Neurobiologic basis of anxiety and its treatment. Harvard Rev Psychiatry. 1993;1:197-206.
2. Haefely W. The GABA-benzodiazepine interaction fifteen years later. Neurochemi Res. 1990;15:169-174.
3. Skolnick P, Paul SM. Benzodiazepine receptors in the central nervous system. Int Rev Neurobiol. 1982; 23:103-140.
4. Arana G, Hyman S. Benzodiazepines and other anxiolytic drugs. In: Handbook of Psychiatric Drug Therapy, 2nd ed. Little, Brown & Co. Boston, MA. 1991:128-161.
5. Zorunski OF, Isenberg KE. Insights into the structure and function of GABA benzodiazepine receptors: ion channels and psychiatry. Am J Psychiatry. 1991;148:162-163.
6. Paul SM, Purdy RH. Neuroactive steroids. FASEB J. 1992;6:2311-2322.
7. Deutsch SI, Mastropaolo J, Hitri A. GABA-active steroids: endogenous modulators of GABA-gated chloride ion conductance. Clin Newropharmacol. 1992;15:352-364.
8. Crowley DS, Roy-Byme RP, Greenblatt DJ. Benzo - diazepines: Pharmacokinetics and pharmacodynamics. In: Roy-Byrne PP, Crowley DS, eds. Benzodiazepines in clinical practice: risks and benefits. American Psychiatric Press. Washington, DC. 1991;21-32.
9. Charney DS, Heninger GR. Noradrenergic function and the mechanism of action of antianxiety treatment, I: the effect of long term alprazolam treatment. Arch Gen Psychiatry. 1985;42:458-67.
10. Pyke RE, Greenberg HS. Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders. J Clin Psychopharmacol. 1989;9:15-21.
11. Ashton, H. Toxicity and adverse consequences of Benzodiazepine use. Psychiatric Annals. 1995;25:3:158-165.
12. Miller LG, Greenblatt DJ, Paul SM, Shader RI. Benzodiazepine receptor occupancy in viva: correlation with brain concentrations and pharmacodynamic actions. J Pharmacol Exp Ther. 1987;1398-1405.
13. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993;1398-1405.
14. Kennett GA. Mechanisms of serotonergic affect control. In: Schwarcz R, Young SN, Brown RR, eds. Kynurenine and serotonin pathways. New York: Plenus Press, 1991.
15. Pei Q, Zetterstrom T, Fillenz M. Both systemic and local administration of benzodiazepine agonists inhibit the in vivo release of 5-HT in ventral hippocampus. Neuropharmacology. 1989;28:1061-1066.
16. Pratt J, Jenner P, Reynolds EH, Marsden CD. Clonazepam induces decreased serotonergic activity in the mouse brain. Neuropharmacology. 1979;18:791-799.
17. Trulson ME, Preussler DW, Howell GA, Fredrickson CJ. Raphe unit activity in freely moving-cats: effects of benzodiazepines. Neuropharmacology. 1982;21:1050-1080.
18. Verge D, Davel G, Patel A, Gozlam H, Mestikaway S, Hamon M. Presynaptic 5HT autoreceptors on serotonergic cell bodies and/or dendrites but not terminals are of the 5-HT1A subtype. Eur J Pharmacol. 1985;113:463-464.
19. Lucki, I. Serotonin receptor specificity in anxiety disorders. J Clin Psychiatry. 1996;57(6, Suppl.):5-10.
20. Grahame-Smith DG. The neuropharmacology of 5-HT in anxiety. In: Briley M, File SE, eds. New Concepts in Anxiety. Boca Raton, Florida: CRC Press, 1991:46-55.
21. Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science. 1980;210:87-89.
22. Gonzlaes-Heydrick J, Peroutka SJ. Serotonin receptor and reuptake sites: pharmacologic significance. J Clin Psychiatry. 190;5(4, Suppl.):5-12.
23. Longo, LP. Non-benzadiazepine pharmacotherapy of anxiety and panic in substance abusing patients. Psychiatric Annals (in press).
24. Chamey DS, Henninger GR. Abnormal regulation of noradrenergic function in panic disorders. Am J Psychiatry. 1986;43:1042-1054.
25. Chamey DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry. 1988;46:165-169.
26. Nutt DJ. Altered central alpha2-adrenoreceptor sensitivity in panic disorder. Arch Gen Psychiatry. 1988; 46: 165-169.
27. Nutt DJ. Increased central alpha-2 adrenoreceptor sensitivity in panic disorder. Psychopharmacology. 1986; 90:268-269.
28. Tyrer P. Anxiolytics not acting at the benzodiazepine receptor: beta blockers. Prog Neuropsychopharmacol Biol Psychiatry. 1992;16:17-26.
29. Hayes PE, Schultz SO. Beta-blockers in anxiety disorders. J Affect Disord. 1987;13:119-130.
30. Lader M. Beta-adrenoceptor antagonists in neuropsychiatry: an update. J Clin Psychiatry. 1988;49:213-223.
31. Hoehn-Saric R, Merchant AF, Keyser MC, and Smith VK. Effects of clonidine on anxiety disorders. Arch Gen Psychiatry. 1981;38:1278-1282.
32. Charney DS, Stemberg DE, Kleber HD, Heninger DE, Redmond DE. The clinical use of clonidine in abrupt withdrawal from methadone. Arch Gen Psychiatry. 1981;38: 1273-1277.
33. Bond WS. Psychiatric indication for clonidine: The neuropharmacologic and clinical basis. J Clin Psychopharmacol. 1986;6:81-87.
34. Glue P, Nutt DJ. Clonidine in alcohol withdrawal: a pilot study of differential symptom responses followng i.v. clonidine. Alcohol Alcoholism. 1987;22:161-166.
35. Glassman AH, Jackson WK, Walsh BT, Roose SP, Rosenfeld B. Cigarette craving, smoking withdrawal, and clonidine. Science. 1984;226-864-866.
36. Trullas R, Winslow JT, Insel TR, Skolnick P. Are glutamatergic pathways involved in pathophysiology of anxiety? In: Briley M, File SE, eds. New Concepts in anxiety. CRS Press. Boca Raton, Fla. 1991:382-394.
37. Stephens DN, Andrews TS, Turski L, Schneider HH. Excitatory neurotransmitters and anxiety. In: Briley M, File SE, eds. New Concepts in anxiety. CRS Press. Boca Raton, FLA. 1991:367-381.
38. Cotman CW, Monaghan DT: Chemistry and anatomy of excitatory amino acid systems, in psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven Press, 1987.
39. Hollmann M, Heinemann S: Cloned glutamate receptors. Annu Rev Neurosci. 1994;17:31-108.
40. Jeffery KJ, Reid IC. Modifiable neuronal connections: an overview for psychiatrists. Am J Psychiatry. 1997; 154:156-164.
41. Tsai G, Gastfriend OR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry. 1995; 152:332-340.
42. Hoffman PL, Tabakoff B. The role of the NMDA receptor in ethanol withdrawal. In: Jansson B, Jornvall H, Tydberg U, Terenius L, Valle BL (eds). Toward a molecular basis of alcohol use and abuse. Birkhauser, Basel. 1994. 61-70.
43. Engberg G, Hajos M. Ethanol attenuates the response of locus coeruleus neurons to excitatory amino acid agonists in viva. Naunyn Schmiedebergs Arch Pharmacol. 1992; 345:222-226.
44. Lustig HS, Chan J, Greenberg DA. Ethanol inhibits excitotoxicity in cerebral cortical cultures. Neurosci Lett. 1992; 135:259-261.
45. Lovinger DM. Ethanol and the NMDA receptor: Implications for intoxication, tolerance, dependence, and alcoholic brain damage. In, Soyka M (ed.) Acamprosate in relapse prevention of alcoholism. Proceedings of the 1st CAMPRAL-Symposium-ESBRA. Stuttgart, 1995.
46. Becker HO, Hale RL. Repeated episodes of ethanol withdrawal potentate the severity of subsequent withdrawal seizures: an animal model of alcohol withdrawal Kindling. Alcohol Clin Exp Res. 1993;17:94-98.
47. Grant KA, Valverius P, Hudspith M, Tabakoff B. Ethanol withdrawal seizures and the NMDA receptor complexes. Eur J Pharm. 1990;176(3):289-296.
48. Sass H, Soyka M, Mann K, Ziegigansberger W. Relapse prevention by acamprosate. Arch Gen Psychiatry. 1996;53:673-680.
49. Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor. Trends Neurosci. 1987;10:299-302.
50. Stanford, SC. Central adrenoceptors in response and adaptation to stress. In: Marsden CA and Heal DJ (ads). The Pharmacology of Noradrenaline in the Central Nervous System. Oxford University Press, Oxford. 1990:379-422.
51. Stone EA. Problems with current catecholamine hypotheses of antidepressant agents: speculations leading to a new hypothesis. Behav Brain Sci. 1983;6:535-577.
52. Stanford SC, Taylor SC, Little HJ. Chronic desipramine treatment prevents the upregulation of cortical beta-receptors caused by a single dose of the benzodiazepine inverse agonsit FG 7142. Eur J Pharmacol. 1987;139:225-232.
53. Dorow R, Horowski R, Paschelke G, Amin M, Braestrup C. Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors. Lancet. 1983;2:98-99.
54. Stanford SC, Little HH, Nutt DJ, and Taylor SC. A single dose of FG 7142 causes long-term increases in mouse cortical beta-adrenoceptors. Eur J Pharmacol. 1986; 134:313-319.
55. Stanford SC, Little HJ, Nutt DJ, and Taylor SC. Effects of chronic treatment with benzodiazepine receptor ligands on cortical adrenoceptors. Eur J. Pharmacol. 1986;129:181-184.
56. Koob G, Bloom FE. Corticotrophin-releasing factor and behavior. Fed Proc. 1985;44:259-265.
57. Vale W, Speiss J, Rivier C, Rivier J. Characterization of a 41-residue ovine by hypothalamic peptide that stimulates secretion of corticotrophin and betaendorphin. Science. 1981;213:1394-1397.
58. Al-Damiuji S, Perry L, Tomlin S, Bouloux , Grossman A, Rees LH, Besser GM. Alpha-adrenergic stimulation of corticotrophin secretion by a specific central mechanism in man. Neuroendocrinology. 1987;45:68-76.
59. Valentino RJ, Foote SL, Aston-Jones G. Corticotrophin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res. 1983;270:363-367.
60. Weiss SRB, Post RM, Gold PW, Chrousos GP, Sullivan TL, Walker DL, Pert A. CRF-induced seizures and behavior: interaction with amygdala kindling. Brain Res. 1986;372:345-351.
61. Klein DF. Anxiety reconceptualized. In: Anxiety. New Research and Changing Concepts. Klein DF, Rabkin J. eds. Raven Press.1981:235-263.
62. Carroll B, Feinberg M, Greden J, Tarika J, Alabala A, Haskett R, James N, Kronfol Z, Lohr N, Steiner M, et al. A specific laboratory test for the diagnosis of melancholia: standardization, validation, and clinical utility. Arch Gen Psychiatry. 1981;38:15-22.
63. Nemeroff C, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosed PT, Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 1982; 218:1332-1334.
64. Roy A, Picklar D, Linnoila M, Chrousos GP, Gold PW. Cerebrospinal fluid corticotropin-releasing hormone in depression: relationship to noradrenergic function. Psychiat Res. 1987;20:229-237.
65. Nutt DJ, Glue P. Clinical pharmacology of anxiolytics and antidepressants: a psychopharmacological perspective. In: File, SE (ed.) Psychopharmacology of Anxiolytics and Antidepressants. Pergom Press, Inc. New York. 1991;1-28.
66. Roy A, Pickar D, Gold P, Barbaccia M, Guidotti A, Costa E, Linnoila M. Diazepam-binding inhibitor and corticotropin-releasing hormone in cerebrospinal fluid. Acta Psych Scand. 1989;803:287-291.
67. Ferrarese C, Appolonio I, Bianchi G, Frigo M, Marzorati C, et al. BZ receptors and diaxepam binding inhibitor: a possible link between stress, anxiety, and the immune system. Psychoneuroendocrinology. 1993;18:3-22.
68. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry. 1996;153:151-162.
69. Heninger GR, Charney DS. Mechanism of action of antidepressant treatments: implications for the etiology and treatment of depressive disorders, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven Press, 1987; 535-544.
70. Sulser F. New perspectives on the molecular pharmacology of affective disorders. Eur Arch Psychiatr Newrol Sci. 1989;238:231-239.
71. Segal DS, Mandell AJ. Long-term administration of amphetamine: progressive augmentation of motor activity and sterotype. Pharmacal Biochem Behav. 1974;2:249-255.
72. Robinson TE, Jurson PA, Bennett JA, Bentgen KM. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res. 1988;462:211-222.
73. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev. 1993;18:247-291.
74. Bliss TVP, Gardner-Medwin AR. Long-lasting potentiation of synaptic transmission in the dentate area of the unanesthetised rabbit following stimulation of the perforant path. J Physiol. 1973;232:357-374.
75. Bliss TVP, Lomo T. Long-lasting potentiation of synaptic transmission in the dentte area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973;232:331-356.
76. Jeffery KJ, Reid IC. Modifiable neuronal connections: An overview for psychiatrists. Am J Psychiatry. 1997;154: 156-164.
77. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurons. Nature. 1984;307:462-465.
78. Sinclair JG, Lo GF: Ethanol blocks tetanic and calcium-induced long-term potentiation in the hippocampal slice. Gen Pharmacol. 1986;17:231-233.
79. Lustig HS, Chan J, Greenberg DA. Ethanol inhibits excitotoxicity in cerebral cortical cultures. Neurosci Lett. 1992; 135:259-261.
80. Engberg G, Hajos M. Ethanol attenuates the response of locus coeruleus neurons to excitatory amino acid agonists in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1992:345:222-226.
81. Murphy JM, Cunningham SD, McBride WJ. Effects of 250 mg% ethanol on monoamine and amino acid release from rat striatal slices. Brain Res Bull. 1985;14:439-442.
82. Iorio KR, Tabakoff B, Hoffman PL: Glutamate induced neurotoxicity is increased in cerebellar granule cells exposed chronically to ethanol. Eur J Pharmacol. 1993;248:209-212.
83. Davidson MD, Wilce , Shanley BC. Increased sensitivity of the hippocampus in ethanol-dependent rats to toxic effect of N-methyl-D aspartic acid in vivo. Brain Res. 1993;606:5-9.
84. Linnoila M, Mefford I, Nutt D, Adinoff B. Alcohol withdrawal and noradrenergic function. Ann Infern Med. 1987;107:875-879.
85. Nestler EJ. Molecular mechanisms of drug addiction. J Neurosci. 1992;12:2439-2450.
86. Nestler EJ, Alreia M, Aghaianian GK. Molecular and cellular mechanisms of opiate action: studies in the rat locus coeruleus. Brain Res Bull. 1994;5:521-528.
87. Aghananian G. Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine. Nature. 1978;267:186-188.
88. Miller LG. Chronic benzodiazepine administration: from the patient to the gene. J Clin Pharmacol. 1991;31: 492-495